Effects of CYP3A4 and MDR1 genetic polymorphism on dosage and concentration of tacrolimus in allogeneic hematopoietic stem cell transplantation patients

Liangping YU,Hua OUYANG,Quanyi LU,Peiyu LYU,Yamei CHEN,Xiaoyan WANG
DOI: https://doi.org/10.19577/j.cnki.issn10074406.2017.02.006
2017-01-01
Abstract:AIM To evaluate the effects of CYP3A4 and MDR1 genetic polymorphism on the concentration,dosage and adverse drug reaction of tacrolimus in allogeneic hematopoietic stem cell transplantation patients.METHODS The CYP3A4 * 18B and MDR1 C3435T genotype were detected by direct sequencing method.The differences ofp0/D0'ratio,D',acute graft versus host disease and adverse drug reaction were compared among different genotype groups treated with tacrolimus.RESULTS Totally 16 patients were involved in this study.The frequencies of CYP3A4 * 18B and MDR1 C3435T alleles were 34.38% and 43.75%,respectively.The p0/D0'of tacrolimus in CYP3A4 * 1/* 1 genotype groups was significantly higher than that of * 18B allele carriers (P <0.05),and the D'was lower than * 18B allele carriers obviously (P < 0.05).No significant association was found between the p0/D0',D'of tacrolimus and MDR1 C3435T genotypes (P >0.05).There was also no significant correlation between CYP3A4 * 18B and MDR1 C3435T gene polymorphisms and acute graft versus host disease and adverse drug reactions induced by tacrolimus (P > 0.05).CONCLUSION CYP3A4 * 18B genetic polymorphism in hematopoietic stem cell transplantation patients is closely correlated to the p0/D0'ratio and D'of tacrolimus.
What problem does this paper attempt to address?